Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

Bevacizumab, an antibody against vascular endothelial growth factor (VEGF), is a promising, yet controversial, drug in human glioblastoma treatment (GBM). Its effects on tumor burden, recurrence, and vascular physiology are unclear. We therefore determined the tumor response to bevacizumab at the ph...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the National Academy of Sciences - PNAS 2011-03, Vol.108 (9), p.3749-3754
Hauptverfasser: Keunen, Olivier, Johansson, Mikael, Oudin, Anaïs, Sanzey, Morgane, Rahim, Siti A. Abdul, Fack, Fred, Thorsen, Frits, Taxt, Torfinn, Bartos, Michal, Jirik, Radovan, Miletic, Hrvoje, Wang, Jian, Stieber, Daniel, Stuhr, Linda, Moen, Ingrid, Rygh, Cecilie Brekke, Bjerkvig, Rolf, Niclou, Simone P., Klein, George
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!